



## **Supplementary Figures and Tables**

**Hemmer et al.**

*E47 mediates hepatic glucocorticoid action*

# Supplementary Figure 1: E2A expression and genomic binding in mouse liver.




GO: Biological process	FDR Q-value
Cellular amino acid metabolic process	1.14e-2
Carboxylic acid catabolic process	2.23e-2
Inactivation of MAPK activity	2.14e-2

**Examples:**  
Got1, Idh1, Acad11, Dusp8, Smc2

GO: Biological process	FDR Q-value
Small molecule metabolic process	1.52e-42
Carboxylic acid metabolic process	9.43e-37
Lipid metabolic process	6.99e-28
Fatty acid metabolic process	5.94e-20
Cellular carbohydrate metabolic process	9.28e-12


**Examples:**  
Abca6, Acot11, Elovl5, Dgat2, Cpt1a

## Supplementary Figure 2: Phenotypic characteristics and gene expression data from *E47*<sup>-/-</sup> mice.



**A:** qRT-PCR of E47 and E12 expression in mouse livers after Dex treatment, normalized to U36b4. Data are expressed as mean  $\pm$  SEM, (\*\*\*) P<0.0001, Student's t-test, n=10 (WT) & 7 (E47<sup>-/-</sup>). **B:** i.p. GTT and **C:** i.p. PTT in untreated E47<sup>-/-</sup> and WT mice. Data were analyzed by ANOVA and Bonferroni's multiple comparison test and are shown as mean  $\pm$  SEM, n= 9 (WT) & 15 (E47<sup>-/-</sup>) for GTT; n= 6 (WT) & 7 (E47<sup>-/-</sup>) for PTT. **D:** Liver and plasma triglycerides in untreated mice. Data are mean  $\pm$  SEM, n= 10 per genotype (liver); n= 3 (WT) & 4 (E47<sup>-/-</sup>) (plasma). **E:** Volcano plot and GO analysis of differentially expressed genes (blue= down-; red=up-regulated) in untreated mouse livers (FC 1.3, P<0.05, n= 5 (WT) & 6 (E47<sup>-/-</sup>)). For GO analysis a base mean cutoff >200 was used. **F:** Body weight of untreated E47<sup>-/-</sup> and WT mice. Data are mean  $\pm$  SEM, n= 7 (WT) & 9 (E47<sup>-/-</sup>). **G:** Fat mass gain as percentage of body weight after Cort treatment. Data are mean  $\pm$  SEM, n=8 (WT) & 11 (E47<sup>-/-</sup>). **H:** Plasma corticosterone of mice 6hrs after injection of 1mg/kg Dex or vehicle. Data are mean  $\pm$  SEM, UT: n=7 per genotype; Dex-injected: n=6 (WT) & 5 (E47<sup>-/-</sup>). **I:** Average number of normalized NGS read counts for Adipoq in Dex-treated white adipose tissue. Data are mean  $\pm$  STDEV, n=2 per genotype. **J:** Volcano plot and GO analysis of differentially expressed genes (blue= down-; red=up-regulated) in white adipose tissue (WAT) and skeletal muscle (SM) (**K**) of E47<sup>-/-</sup> mice on Dex (FC 1.3, P<0.05); For GO analysis a base mean cutoff >200 was used; SM: n=2 (WT) & 3 (E47<sup>-/-</sup>); WAT: n= 2 per genotype. **L:** qRT-PCR in macrophages isolated from E47<sup>-/-</sup> and WT mice and treated with LPS or LPS+Dex, normalized to U36b4; data are mean  $\pm$  STDEV (\*\* P<0.01, (\*\*\*) P<0.001, Student's t-test, n=2 per genotype).


### Supplementary Figure 3: Measurements in *E47* liver specific mutant mice.




**A:** qRT-PCR of *E47* and *E12* expression in livers after Dex treatment, normalized to U36b4. Data are mean  $\pm$  SEM, (\*\*\*) P<0.0001, Student's t-test, n= 7 (Ctrl) & 5 (*E47*<sup>ΔLKO</sup>). **B:** Area under the curve (AUC) of GTT (Fig. 3A). Student's t-test was performed on AUC, (\*\*) P<0.01 **C:** i.p. GTT in untreated *E47*<sup>ΔLKO</sup> and control mice. Data were analyzed by ANOVA and Bonferroni's multiple comparison test and are mean  $\pm$  SEM, n=10 (WT) & 11 (*E47*<sup>ΔLKO</sup>). **D:** Body weight of untreated *E47*<sup>ΔLKO</sup> and control mice. Data are mean  $\pm$  SEM, n=7 per genotype. **E:** Fat mass gain as percentage of body weight on Cort. Data are mean  $\pm$  SEM, n=8 per genotype. **F:** Number of genes differentially expressed in *E47* mutant mice with a nearby GR ChIP peak (see Fig. 3G).

## Supplementary Figure 4: Expression levels and binding in mutant mice.


**A**




**B**




**C**



**D**




**E**



**A:** Number of normalized read counts for Med1, Med23, Med16, Foxo1, GR, Lxra and Lxrβ from RNA-Seq data in livers either untreated (UT), Cort or Dex treated or Dex-injected (Fig. 2&3 and Suppl. Fig. 2). Data are mean ±STDEV. **B:** Immunostaining for GR in Dex-injected E47<sup>-/-</sup> and WT livers co-stained with DAPI, 63x magnification (75μm), confocal microscopy. **C:** Western blot of nuclear extracts from Dex-treated WT and E47<sup>-/-</sup> livers. Immunoblot (IB) for GR and Snrnp70. **D:** Co-IP of GR and E2A in Dex-treated WT livers. Immunoblot (IB) for 30% input and IP against GR. **E:** ChIP-qPCR in Cort-treated E47<sup>ΔLKO</sup> and control livers shows binding of GR & Med1 at metabolic promoters/enhancers. Data are shown as fold enrichment over IgG (n= 4 (Ctrl) and 6 (E47<sup>ΔLKO</sup>)). Data are mean ±SEM, (\*) P<0.05, (\*\*) P<0.01, Student's t test.

## Supplementary Figure 5: Data from fasted *E47* mutants.



**A:** ChIP-qPCR in fasted  $E47^{\Delta\text{LKO}}$  and control livers shows binding of Foxo1 at metabolic promoters/enhancers. Data are shown as fold enrichment over IgG, n= 6 (Ctrl) and 4 ( $E47^{\Delta\text{LKO}}$ ). Data are mean ± SEM. **B:** Plasma corticosterone levels of untreated  $E47^{-/-}$  mice and wildtype littermates, n=7 per genotype (Data taken from Supplementary Figure 2H). **C:** Plasma corticosterone levels of 48h-fasted  $E47^{-/-}$  mice and wildtype littermates, n=8 (WT) & 5 ( $E47^{-/-}$ ). **D:** Blood glucose levels of  $E47^{\Delta\text{LKO}}$  mice and control littermates measured at 24hrs and 48hrs of fasting. Data are mean ± SEM, n=4 (Ctrl) & 5-6 ( $E47^{\Delta\text{LKO}}$ ). **E:** Liver triglycerides in 48h-fasted  $E47^{-/-}$  mice and wildtype littermates. Data are mean ± SEM, n= 4 (Ctrl) & 6 ( $E47^{\Delta\text{LKO}}$ ).

**Supplementary Table 1a: Primers for ChIP qPCR**

Abbreviation	Forward primer (5'-3')	Reverse primer (3'-5')
<b>Acacb</b>	CAGGCAGCGAGCATTCTTA	TCTGATGCCCTGTGCCTAC
<b>Apoa4</b>	TCACTGGGTGGAAAGAGGA	CCTGAACAGAACTGAGGCC
<b>Cyp2a22</b>	AAGGCCATCATGTACCTGGC	TGGCATGGATCTACAAAGGCT
<b>Cyp2c39</b>	GGGTTACTCAACGATGCTCAA	TTGTGATCAGGCATCACTGGC
<b>Dhcr7</b>	CCTGCGTAGCTGGTTCTTA	CAGAAGCTGGCTATGACGG
<b>Dhcr24</b>	CTGGATGCCCTGTGAGTTCTA	ACAGGCATTGCAAACATACT
<b>G6pc</b>	CAGGACGAAGGGAGAGAGC	AGTCAGGCTGAGGACCTTG
<b>Gck</b>	GCTGTGGGTGAGGACTGTCT	TTTAGGAGCCACCTCTCAGACT
<b>Gpam</b>	ACACACAAGGAGGAGTGCAG	CACGGTTGCCAATGAGTTA
<b>Hmgcr</b>	GGCCGCCAATAAGGAAGGAT	GGAGACCGTTGACGTAG
<b>Hmgcs1</b>	TGGTCGGAGAACCTCTCACT	CGAGAACAAAGCCTGCCAATG
<b>Igfbp1</b>	CAGCACTTCCACC GTTGAC	GCAGCTCCAGAGTTAGGCAA
<b>Pck1</b>	CAGGGCTGTCCCTCCCTTCTA	CTGTTGACCGAGGGTGTGTT
<b>nCtrl</b>	GCTGGCAGAATAGCATCCG	TGATGAAGCACTCGTTGAGGC

**Supplementary Table 1b: Primers for mRNA**

Abbreviation	Forward primer (5'-3')	Reverse primer (3'-5')
<b>Acacb</b>	CCTTGCGAACAGCAAGGTA	AGTCGTACACATAGGTGGTCC
<b>Apoa4</b>	CGTGGACCTGCAAGATCAGA	TCTGCATGCGCTGGATGTAT
<b>Ccl2</b>	TTAAAAACCTGGATCGGAACCAA	GCATTAGCTTCAGATTACGGGT
<b>Cyp2a22</b>	GTCACTCGCCTCTGCAAAC	TGTACACTGGCTTGGGAAC
<b>Cyp2c39</b>	GAGGAAGCATTCAAATGGTAGAA	TGTGAAGCGCCTAATCTCTTC
<b>Dhcr7</b>	AGCTTCAGGCAGGCACTTAG	TGCTGGATTTCGAAGCCAT
<b>Dhcr24</b>	CTGAAGACAAACCGGGAGGG	AAGATGGGTTTGTGCCGAA
<b>E12</b>	TGCAGGATGAGCAGTTGGT	GAGGCCTTAAGGAGCTCGG
<b>E47</b>	TTATCCGACTTGAGGTGCAG	CTGGAGGAGAAGGACCTGAG
<b>Gck</b>	AACGACCCCTGCTTATCCTC	CTTCTGCATCCGGCTCATCA
<b>Gpam</b>	CTTCTAAGTCACCCACACCTGG	TTGCTTACTGGTCTGTATCCT
<b>Gilz</b>	ACCACCTGATGTACGCTGTG	TCTGCTCCTTAGGACCTCCA
<b>G6pc</b>	CGACTCGCTATCTCAAAGTG	GTTGAACCAGTCTCCGACC
<b>Hmgcr</b>	AGCTTGCCCCGAATTGTATGTG	TCTGTTGTGAACCATGTGACTTC
<b>Hmgcs1</b>	GATCCCCTTGGTGGCTGAAG	GAAAGAGCTGTGTGAAGGACAG
<b>Il6</b>	TAGTCCTTCCCTACCCCAATTCC	TTGGTCCTTAGCCACTCCTTC
<b>Igfbp1</b>	TCGTGACCACTGAGCACTG	AGTTAGGAACCTGGGCATCG
<b>Pck1</b>	CTGCATAACGGTCTGGACTTC	CAGCAAACCTCCGTACTCC
<b>U36b4</b>	AGATTGGGATATGCTGTTGGC	TCGGGTCTAGACCAGTGTTC